Lord, Abbett & Co
KPTI icon

Lord, Abbett & Co’s Karyopharm Therapeutics KPTI Stock Holding History

Lord, Abbett & Co’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-7,773
Closed -$3.57M – 959
2015
Q1 		$3.57M Buy
7,773
+3,152
+68% +$1.36M 0.01% 780
2014
Q4 		$2.59M Sell
4,621
-6,504
-58% -$3.69M 0.01% 834
2014
Q3 		$5.83M Buy
11,125
+2,983
+37% +$1.68M 0.01% 716
2014
Q2 		$5.68M Buy
+8,142
New +$3.79M 0.01% 776

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Lord, Abbett & Co's KPTI Position: Q2 2015 in Review

Lord, Abbett & Co sold out of Karyopharm Therapeutics (KPTI) in Q2 2015, closing a stake of 7,773 shares — an estimated $3.57M sold.

Lord, Abbett & Co first reported a position in KPTI in Q2 2014 and held it in 4 quarters. The position peaked at $5.83M in Q3 2014. 89 funds tracked by Wall St. Rank hold KPTI as of Q2 2015.

  • Lord, Abbett & Co reported no remaining Karyopharm Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 7,773 Karyopharm Therapeutics shares in Q2 2015, an estimated $3.57M.
  • Lord, Abbett & Co first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 4 quarters.
  • Lord, Abbett & Co's Karyopharm Therapeutics position peaked at $5.83M in Q3 2014.
  • 89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2015.

Based on Lord, Abbett & Co's 13F filing for Q2 2015, filed 14 Aug 2015.